诺瓦瓦克斯医药(NVAX)2日在美股盘中股价大涨12.09%,截至收盘报13.77美元。该股近期波动较大,今日上涨主要得益于公司新冠疫苗进入全国销售网络,市场对其未来前景抱有期望。
消息显示,诺瓦瓦克斯医药2024-2025年版新冠疫苗已在全美数千家药店和诊所开始提供,有望进一步打开市场。分析人士表示,尽管公司疫苗针对传统毒株,但仍有一定需求,有助于公司营收提升。
杰富瑞集团近期将诺瓦瓦克斯股票评级维持"买入",目标价31美元。分析师认为,疫苗渠道大幅扩张将为公司注入新的增长动力,未来仍存在一定上涨空间。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.